G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone919-213-9835
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees84
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
G1 Therapeutics (NASDAQ:GTHX) Frequently Asked Questions
What is G1 Therapeutics' stock symbol?
G1 Therapeutics trades on the NASDAQ under the ticker symbol "GTHX."
How were G1 Therapeutics' earnings last quarter?
G1 Therapeutics Inc (NASDAQ:GTHX) issued its quarterly earnings results on Wednesday, August, 7th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.73) by $0.09. View G1 Therapeutics' Earnings History.
When is G1 Therapeutics' next earnings date?
What price target have analysts set for GTHX?
7 brokers have issued 12 month price objectives for G1 Therapeutics' stock. Their forecasts range from $45.00 to $74.00. On average, they anticipate G1 Therapeutics' share price to reach $62.60 in the next year. This suggests a possible upside of 193.9% from the stock's current price. View Analyst Price Targets for G1 Therapeutics.
What is the consensus analysts' recommendation for G1 Therapeutics?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last year. There are currently 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for G1 Therapeutics.
What are Wall Street analysts saying about G1 Therapeutics stock?
Here are some recent quotes from research analysts about G1 Therapeutics stock:
- 1. According to Zacks Investment Research, "G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel, small-molecule therapies which address significant unmet needs in the treatment of cancer. The company's product pipeline consists of CDK4/6, Trilaciclib (G1T28), G1T38 and G1T48. G1 Therapeutics, Inc. is based in Research Triangle Park, NC. " (10/18/2019)
- 2. HC Wainwright analysts commented, "We base our $72 price target on probability-adjusted revenue forecasts for trilaciclib in first line SCLC, second and third line SCLC, and metastatic TNB cancer plus lerociclib in ER+, HER2- breast cancer and EGFR mutant NSCLC. We use the net present value of our revenue forecast through 2026, apply a 50% and 40% POS for trilaciclib and lerociclib, respectively, a 3x price/sales multiple, and a $2.93/share value for the early stage pipeline that includes trilaciclib and lerociclib in other indications, and G1T48." (9/11/2019)
Has G1 Therapeutics been receiving favorable news coverage?
News headlines about GTHX stock have been trending somewhat positive on Monday, InfoTrie Sentiment reports. The research firm ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. G1 Therapeutics earned a news impact score of 0.8 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for G1 Therapeutics.
Who are some of G1 Therapeutics' key competitors?
Some companies that are related to G1 Therapeutics include Evotec (EVTCY), Allakos (ALLK), Nektar Therapeutics (NKTR), Global Blood Therapeutics (GBT), Taro Pharmaceutical Industries (TARO), Alkermes (ALKS), Mirati Therapeutics (MRTX), Emergent Biosolutions (EBS), Myokardia (MYOK), Genmab A/S (GMAB), HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE), Arena Pharmaceuticals (ARNA), Biohaven Pharmaceutical (BHVN) and PTC Therapeutics (PTCT).
What other stocks do shareholders of G1 Therapeutics own?
Who are G1 Therapeutics' key executives?
G1 Therapeutics' management team includes the folowing people:
- Dr. Mark A. Velleca, CEO, Pres & Director (Age 55)
- Mr. James Stillman Hanson, Gen. Counsel (Age 47)
- Mr. Terry L. Murdock, Sr. VP of Devel. Operations (Age 59)
- Mr. John Demaree, Chief Commercial Officer (Age 52)
- Ms. Jennifer K. Moses, Chief Financial Officer (Age 44)
When did G1 Therapeutics IPO?
(GTHX) raised $101 million in an IPO on Wednesday, May 17th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.
Who are G1 Therapeutics' major shareholders?
G1 Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (1.43%), Tuttle Tactical Management (0.12%) and Nisa Investment Advisors LLC (0.07%). Company insiders that own G1 Therapeutics stock include Barclay A Phillips, Clay Thorp, Cynthia Schwalm, Fredric N Eshelman, James S Hanson, Jay Strum, Jennifer K Moses, John Demaree, Mark A Velleca, Medimmune Ventures, Inc, Rajesh Malik, Seth Rudnick and Terry L Murdock. View Institutional Ownership Trends for G1 Therapeutics.
Which institutional investors are buying G1 Therapeutics stock?
GTHX stock was acquired by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Tuttle Tactical Management and Nisa Investment Advisors LLC. Company insiders that have bought G1 Therapeutics stock in the last two years include Cynthia Schwalm, Fredric N Eshelman, James S Hanson and John Demaree. View Insider Buying and Selling for G1 Therapeutics.
How do I buy shares of G1 Therapeutics?
Shares of GTHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is G1 Therapeutics' stock price today?
One share of GTHX stock can currently be purchased for approximately $21.30.
How big of a company is G1 Therapeutics?
G1 Therapeutics has a market capitalization of $799.18 million. The company earns $-85,290,000.00 in net income (profit) each year or ($2.56) on an earnings per share basis. G1 Therapeutics employs 84 workers across the globe.View Additional Information About G1 Therapeutics.
What is G1 Therapeutics' official website?
How can I contact G1 Therapeutics?
G1 Therapeutics' mailing address is 79 T.W. Alexander Drive 4501 Research Commons Suite 100, Research Triangle Park NC, 27709. The company can be reached via phone at 919-213-9835.
MarketBeat Community Rating for G1 Therapeutics (NASDAQ GTHX)
MarketBeat's community ratings are surveys of what our community members think about G1 Therapeutics and other stocks. Vote "Outperform" if you believe GTHX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GTHX will underperform the S&P 500 over the long term. You may vote once every thirty days.
